Latest industry research report on: Global Pancreatic Cancer Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
The objective of this report is to define, describe, and forecast the market on the basis of type, application, medical condition, and region. It provides detailed information regarding the major factors influencing the growth of the market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials.
Complete Report Details @ https://www.marketresearchreports.biz/reports/139164/pancreatic-cancer-global-industry-market-research-reports
The global pancreatic cancer drug market is projected to reach USD 1.2 billion by 2015. Among all the regions, the United States has recorded the maximum number of pancreatic cancer cases, which are about 30,000 patients each year. The survival rate is less than 5 years which acts as a major hurdle for the growth of this market.
The aggressive nature of pancreatic cancer and inadequate responses to the treatment acts as major obstacles in the treatment of such diseases. Moreover, pancreatic cancer is diagnosed when it is in its advanced stage, leading to increase in mortality rate of the patients affected by such diseases. Only 15% to 12% of patients are diagnosed early enough thus making it possible to remove the tumor surgically. The stages in pancreatic cancers include stage I, stage II, stage III and stage IV of which only stage I and stage II tumors can be removed surgically.
Request For Sample Report @ https://www.marketresearchreports.biz/sample/sample/139164
Eli Lilly’s Gemzar (Gemcitabine) dominates the pancreatic cancer drug as it is presently the most advanced drug therapy recommended for stage III, IV or advanced stage treatments. Eli Lilly's Gemzar (Gemcitabine) and Genentech/ OSI Pharmaceuticals/ Roche's Tarceva (Erlotinib) have captured the whole of the pancreatic cancer drug market as these are the only two approved therapies available for the treatment of pancreatic cancer. Of the two, Gemzar leads the market with about 55% share in the pancreatic cancer drugs market.
The uncontrolled growth of cells in the pancreas leads to pancreatic cancer. This abnormal cells growth keeps on dividing and forms lumps or a mass of tissues called tumors. Tumors disturb the normal functioning of the pancreas. Pancreatic cancer is classified based on whether it affects exocrine or endocrine functions of the pancreas. The most common type of pancreatic cancer is adenocarcinomas, which account for 95% of exocrine pancreatic cancers. Other types of pancreatic cancers that are associated with endocrine functions include adenosquamous carcinomas, squamous cell carcinomas, and giant cell carcinomas.
Have Any Query? Ask Our Expert @ https://www.marketresearchreports.biz/sample/enquiryBuy/139164
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment